Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of an inactivated virus particle vaccine for SARS-CoV-2, BIV1-CovIran: findings from double-blind, randomised, placebo-controlled, phase I and II clinical trials among healthy adults.
Mohraz M, Salehi M, Tabarsi P, Abbasi-Kangevari M, Ghamari SH, Ghasemi E, Amini Pouya M, Rezaei N, Ahmadi N, Heidari K, Malekpour MR, Nasiri M, Amirzargar AA, Saeedi Moghaddam S, Larijani B, Hosseini H. Mohraz M, et al. Among authors: hosseini h. BMJ Open. 2022 Apr 8;12(4):e056872. doi: 10.1136/bmjopen-2021-056872. BMJ Open. 2022. PMID: 35396297 Free PMC article. Clinical Trial.
Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial.
Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javad-Mousavi SA, Khodashahi R, Darban M, Kalantari S, Abdollahi N, Salehi MR, Rezaei Hosseinabadi A, Khorvash F, Valizadeh M, Dastan F, Yousefian S, Hosseini H, Anjidani N, Tabarsi P. Malekzadeh R, et al. Among authors: hosseini h. Int Immunopharmacol. 2020 Dec;89(Pt B):107102. doi: 10.1016/j.intimp.2020.107102. Epub 2020 Oct 13. Int Immunopharmacol. 2020. PMID: 33075713 Free PMC article. Clinical Trial.
Assessment of BIV1-CovIran inactivated vaccine-elicited neutralizing antibody against the emerging SARS-CoV-2 variants of concern.
Salehi M, Hosseini H, Jamshidi HR, Jalili H, Tabarsi P, Mohraz M, Karimi H, Lotfinia M, Aalizadeh R, Mohammadi M, Ramazi S, Abdoli A. Salehi M, et al. Among authors: hosseini h. Clin Microbiol Infect. 2022 Jun;28(6):882.e1-882.e7. doi: 10.1016/j.cmi.2022.02.030. Epub 2022 Mar 3. Clin Microbiol Infect. 2022. PMID: 35248745 Free PMC article.
Immunogenicity and safety of a bivalent, adjuvant system 04-adjuvanted human papillomavirus vaccine in healthy female volunteers aged 15-25: a randomized, double-blind, phase III, noninferiority clinical trial.
Afshani SM, Mirhassani R, Hosseini H, Hosseini R, Tehranian A, Malekzadeh R, Ostovar A, Abdolghaffari AH, Ghobadi MA, Hedayatjoo B, Hazegh Fetratjoo D, Rezagholi Z, Anari A, Moini A. Afshani SM, et al. Among authors: hosseini r, hosseini h. Eur J Cancer Prev. 2022 Nov 1;31(6):558-567. doi: 10.1097/CEJ.0000000000000753. Epub 2022 Mar 29. Eur J Cancer Prev. 2022. PMID: 35352698 Clinical Trial.
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
Mohraz M, Vahdat K, Ghamari SH, Abbasi-Kangevari M, Ghasemi E, Ghabdian Y, Rezaei N, Pouya MA, Abdoli A, Malekpour MR, Koohgir K, Saeedi Moghaddam S, Tabarsi P, Moghadami M, Khorvash F, Khodashahi R, Salehi M, Hosseini H. Mohraz M, et al. Among authors: hosseini h. BMJ. 2023 Sep 21;382:e070464. doi: 10.1136/bmj-2023-070464. BMJ. 2023. PMID: 37734752 Free PMC article. Clinical Trial.
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M, Alavi Darazam I, Nematollahi A, Alimohammadi M, Pouya S, Alimohammadi R, Khajavirad N, Porgoo M, Sedghi M, Mahdi Sepahi M, Azimi M, Hosseini H, Mahmoud Hashemi S, Dehghanizadeh S, Khoddami V. Salehi M, et al. Among authors: hosseini h. Int Immunopharmacol. 2024 May 17;134:112192. doi: 10.1016/j.intimp.2024.112192. Online ahead of print. Int Immunopharmacol. 2024. PMID: 38761778
COVID-19 vaccines: What dermatologists should know?
Ayatollahi A, Hosseini H, Firooz R, Firooz A. Ayatollahi A, et al. Among authors: hosseini h. Dermatol Ther. 2021 Sep;34(5):e15056. doi: 10.1111/dth.15056. Epub 2021 Jul 13. Dermatol Ther. 2021. PMID: 34232548 Free PMC article. Review.
Evaluation of the safety and efficacy of a biosimilar abobotulinum toxin type A in treating moderate-to-severe glabellar lines: A non-inferiority double blinded randomized controlled trial.
Afshani SM, Samadi A, Ayatollahi A, Kashani MN, Ahmad Nasdrollahi S, Hosseini H, Rezagholi Z, Hedayatjoo B, Hazegh Fetratjoo D, Ghobadi MA, Anari A, Saeedifar S, Firooz A. Afshani SM, et al. Among authors: hosseini h. J Cosmet Dermatol. 2022 Jun;21(6):2398-2406. doi: 10.1111/jocd.14939. Epub 2022 Apr 9. J Cosmet Dermatol. 2022. PMID: 35340107 Clinical Trial.
Efficacy and safety of "Jollab Monzej" as a traditional persian compound medicine for the treatment of multiple sclerosis-related fatigue: A randomized placebo-controlled trial.
Yousefnia Babaki F, Khodadoost M, Rezaeizadeh H, Naser Moghadasi A, Fahimi S, Hosseini H, Movahhed M, Gharagozli K. Yousefnia Babaki F, et al. Among authors: hosseini h. Caspian J Intern Med. 2023 Spring;14(2):257-266. doi: 10.22088/cjim.14.2.257. Caspian J Intern Med. 2023. PMID: 37223302 Free PMC article.
696 results